LEGN (Legend Biotech) Payments of Debt: $-4 Mil (TTM As of Mar. 2026)


LEGN Legend Biotech Corp LEGN
74 GF Score
Price $27.85
GF Value $99.61
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Legend Biotech Payments of Debt?

Legend Biotech LEGN +0.78% 74 Payments of Debt is $-4 Mil as of Mar. 2026. GuruFocus rates LEGN with a GF Score™ of 74/100 and a GF Value™ of $99.61 (Possible Value Trap). The stock has 3 warning signs investors should review.

Legend Biotech's Payments of Debt for the three months ended in Mar. 2026 was $-1 Mil.

Legend Biotech's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was $-4 Mil.

Legend Biotech Payments of Debt Related Terms

Legend Biotech Payments of Debt Historical Data

* Premium members only.

The historical data trend for Legend Biotech's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Legend Biotech Payments of Debt Chart

Legend Biotech Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial -1.42 -2.60 -3.80 -4.00 -3.60

Legend Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.80 -1.24 -0.60 -0.96 -1.30
LEGN
74GF Score
Legend Biotech Corp LEGN
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Legend Biotech Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of $-4 Mil mean?
Legend Biotech (LEGN) has a Payments of Debt of $-4 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Legend Biotech and its competitors.
Is Legend Biotech's Payments of Debt too high?
Legend Biotech's current Payments of Debt is $-4 Mil. Overall, Legend Biotech has a GF Score™ of 74/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Legend Biotech's Payments of Debt compare to TVTX and ORKA?
Legend Biotech's Payments of Debt of $-4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Legend Biotech and its competitors. Legend Biotech's current Payments of Debt is $-4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Legend Biotech stock overvalued right now?
Based on GuruFocus' analysis, Legend Biotech (LEGN) is currently considered Possible Value Trap. The stock's GF Value™ is $99.61, compared to a current price of $27.85 — trading 72% below its estimated fair value. The current Payments of Debt is $-4 Mil. Legend Biotech's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Legend Biotech (LEGN), the current Payments of Debt is $-4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Legend Biotech (LEGN) Overvalued in 2026?

Based on GuruFocus' analysis, Legend Biotech stock appears to be undervalued. The current stock price of $27.85 is trading 72% below its estimated GF Value™ of $99.61. GuruFocus considers Legend Biotech to be Possible Value Trap.

Key valuation signals for LEGN:

  • Payments of Debt: $-4 Mil
  • GF Value™: $99.61 vs. price of $27.85 (72% below fair value)
  • GF Score™: 74/100 with 3 warning signs

No single metric tells the full story. See the LEGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Legend Biotech Business Description

Other Exchanges 9LB:Germany
Address 2101 Cottontail Lane, Somerset, NJ, USA, 08873
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
74GF Score

Get the complete analysis for LEGN

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.85
Price
$99.61
GF Value